Cobro Ventures Co-Leads $170M Financing for C4 Therapeutics

Choate represented Cobro Ventures as a co-lead in the $170M Series B financing round for C4 Therapeutics (C4T), a biotechnology company pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation. With multiple oncology-focused programs poised to enter clinical trials in 2021 and 2022, this investment will allow C4T to advance multiple BiDAC™ degrader candidates to human proof-of-concept.

Cobro Ventures co-led the round with Perceptive Advisors, while additional new equity investors included Adage Capital Management , Bain Capital Life Sciences, RA Capital, RTW Investments, Taiwania Capital Management, and Yonjin Venture, among others.